Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 70

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 70
---
 to the Consummation of the Merger” on page 125 of this proxy statement/prospectus. NLS Meeting (Page 74) Date, Time and Place of the of the NLS Meeting The NLS Meeting will be held at 4 pm, local time, on, 2025, at Advokatur 107, Rorschacher Str. 107, 9000 St. Gallen, Switzerland. NLS will be hosting the NLS Meeting in person to consider and vote upon: •Proposal No. 1 to approve the Merger Agreement. •Proposal No. 2 to approve the ordinary share capital increase with contribution of the Kadimastem shares to implement the Merger. •Proposal No. 3 to approve the ordinary share capital increase regarding the issuance of preferred shares. •Proposal No. 4 to approve the reinstatement of the capital band. •Proposal No. 5 to approve the conditional share capital for employee and advisory options. •Proposal No. 6 to approve the conditional share capital for shareholders’ options. •Proposal No. 7 to approve the transfer and voting rights limitation of 9.99%. •Proposal No. 8 to approve the name change of NLS. •Proposal No. 9 to approve the election of the new members to the NLS Board. •Proposal No. 10 to approve the election of members of the Compensation, Nomination and Governance Committee. •Proposal No. 11 to approve the composition of the new senior management following the Merger. •Proposal No. 12.1 to approve the compensation for the members of the NLS Board. •Proposal No. 12.2 to approve compensation for the executive officers. •Proposal No. 13 to approve the CVR Agreement. •Proposal No. 14 to approve the conversion of outstanding options and RSUs issued by Kadimastem. Purpose of the NLS Meeting NLS is holding the NLS Meeting for the following purposes: 1.To approve, on an advisory basis, the Merger Agreement. 2.To approve the increase of the share capital of the Company, by way of an ordinary capital increase, by up toOrdinary Shares, and up to a maximum of CHF, to create the required number of the Company Common Shares to be issued at the effective time of the Merger to the shareholders of Kadimastem in exchange for their Kadimastem Ordinary Shares. 4 3.To approve the increase of the share capital of